- Home
- RLAY vs NBXG Comparison
RLAY vs NBXG Comparison
Compare RLAY & NBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLAY | NBXG |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RLAY | NBXG |
|---|---|---|
| Price | $9.72 | $13.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 266.7K |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,355,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $178.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.44 | N/A |
| 52 Week Low | $1.78 | $10.94 |
| 52 Week High | $11.43 | $15.66 |
Technical Indicators
Market Signals| Indicator | RLAY | NBXG |
|---|---|---|
| Relative Strength Index (RSI) | 59.25 | 37.29 |
| Support Level | $7.22 | $13.09 |
| Resistance Level | $11.43 | $15.00 |
| Average True Range (ATR) | 0.68 | 0.27 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 43.23 | 4.12 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.